Browsing by Author Kichenadasse, G

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2014Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)Boland, Amy; Chatfield, Mark; Gebski, Val; Grimison, Peter; Houghton, Baerin; Stockler, Martin; et al, Various; Friedlander, Michael; Gruney, H; Kichenadasse, G; Lewis, Craig; Rosenthal, M; Singhal, N; Thomson, D B; Toner, Guy C.; Vasey, P; Wong, S; Northern Clinical School: Medicine; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAccelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Annals of Oncology, vol.25, 1, 2014,pp 143-148
2016Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trialBack, Michael; Khasraw, Mustafa; Lee, Adrian; Wheeler, Helen; Ackland, Stephen; Buyse, Marc E.; Kerestes, Z; Kichenadasse, G; McCowatt, Sally; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; Northern Clinical School: MedicineCilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, Journal of Neuro-Oncology, vol.128, 1, 2016,pp 163-171
2016Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trialBack, Michael; Khasraw, Mustafa; Lee, Adrian; Wheeler, Helen; Ackland, Stephen; Buyse, Marc E.; Kerestes, Z; Kichenadasse, G; McCowatt, Sally; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; Northern Clinical School: MedicineCilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, Journal of Neuro-Oncology, vol.128, 1, 2016,pp 163-171
2015EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma.Espinoza, David; Hudson, Amanda; Long, Anne; Martin, Andrew; Pavlakis, Nick; Stockler, Martin; Thompson, John; Yip, Sonia; Azad, A; Davis, I D; Goldstein, David; Harrision, M; Harvie, R; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Lowenthal, Raymond M.; Nelson, C C; Shapiro, J; Steer, C; NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Central Clinical School: Surgery; NH&MRC Clinical Trials CentreEVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma., Annals of Oncology, vol.26, 6, 2015,pp 1118-1123
2013Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG studyBrand, Alison; Donohue, Mark; Gainford, Corona; Gebski, Val; Martyn, Julie; Stockler, Martin; Blinman, Prunella L; Bloomfield, Penny; Friedlander, Michael L.; Grant, Peter Thomas; Kichenadasse, G; Shannon, Catherine; Vaughan, Michelle; Western Clinical School: Medicine (Westmead); Linguistics; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFeasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study, Journal of Gynecologic Oncology, vol.24, 4, 2013,pp 359-366
2017Kinase inhibitor pharmacokinetics: Comprehensive summary and roadmap for addressing inter-individual variability in exposureGurney, Howard; Kichenadasse, G; Mangoni, Arduino; McKinnon, Ross; Miners, John O; Rowland, Andrew; Rowland, Angela; Sorich, Michael; van Dyk, Madele; Wiese, Michael; Western Clinical School: Medicine (Westmead)Kinase inhibitor pharmacokinetics: Comprehensive summary and roadmap for addressing inter-individual variability in exposure, Expert opinion on drug metabolism & toxicology, vol.13, 1, 2017,pp 31-49
2013Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyBoland, Amy; Chatfield, Mark; Gebski, Val; Grimison, Peter; McDonald, Angus; Olver, Ian Norman; Stockler, Martin; Davis, Ian; Harrup, Rosemary; Kichenadasse, G; Singhal, Nimit; Thomson, Damien; Toner, Guy; Underhill, Craig; Northern Clinical School: Medicine; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Ctr for Values Ethics & Law in Med; School of Public Health: NH&MRC Clinical Trials CentreResults of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy, Supportive Care in Cancer, vol.21, 6, 2013,pp 1561-1568